{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:19Z","timestamp":1790803579393,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2019,2,5]]},"DOI":"10.1007\/s40272-018-0318-9","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T01:09:55Z","timestamp":1543367395000},"page":"47-58","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Serious Adverse Events Associated with Off-Label Use of Azithromycin or Fentanyl in Children in Intensive Care Units: A Retrospective Chart Review"],"prefix":"10.1007","volume":"21","author":[{"given":"Kazeem A.","family":"Oshikoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerold T.","family":"Wharton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Avant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara L.","family":"Van Driest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Norman E.","family":"Fenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Lardieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Doe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beena G.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Taketomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong","family":"Lieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilly","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann W.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"issue":"18","key":"318_CR1","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.2012.3435","volume":"307","author":"A Sachs","year":"2012","unstructured":"Sachs A, Avant D, Lee C, Rodriguez W, Murphy D. Research letter: pediatric information in drug product labeling. JAMA. 2012;307(18):1914\u20135.","journal-title":"JAMA"},{"key":"318_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/pds.858","volume":"13","author":"M Ufer","year":"2004","unstructured":"Ufer M, Kimland E, Bergman U. Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Saf. 2004;13:147\u201352.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"318_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/bcp.12222","volume":"77","author":"JR Bellis","year":"2014","unstructured":"Bellis JR, Kirkham JJ, Nunn AJ, Pirmohamed M. Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. Br J Clin Pharmacol. 2014;77:545\u201353.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"318_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bcpt.12445","volume":"117","author":"L Aagaard","year":"2015","unstructured":"Aagaard L. Off-label and unlicensed prescribing of medicines in pediatric populations: occurrence and safety aspects. Basic Clin Pharmacol Toxicol. 2015;117(4):215\u20138.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"318_CR5","unstructured":"Food and Drug Administration, HHS. 21 CFR 314.80: Post marketing reporting of adverse drug experiences 2017. https:\/\/www.gpo.gov\/fdsys\/pkg\/CFR-2011-title21-vol5\/pdf\/CFR-2011-title21-vol5-sec314-80.pdf. Accessed 30 Jul 2017."},{"issue":"11","key":"318_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/1741-7015-11-238","volume":"7","author":"JR Bellis","year":"2013","unstructured":"Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, et al. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. BMC Med. 2013;7(11):238. https:\/\/doi.org\/10.1186\/1741-7015-11-238.","journal-title":"BMC Med."},{"key":"318_CR7","unstructured":"Alamu JO. Evaluation of antimicrobial use in a pediatric intensive care unit. Ph.D. (Doctor of Philosophy) thesis, University of Iowa. 2009. http:\/\/ir.uiowa.edu\/etd\/277. Accessed 06 Jun 2017."},{"key":"318_CR8","first-page":"125","volume-title":"Pediatric sedation outside of the operating room: a multispecialty international collaboration","author":"JD Tobias","year":"2015","unstructured":"Tobias JD. Sedation in the intensive care unit: challenges, outcomes, and failure strategies. In: Manson KP, editor. Pediatric sedation outside of the operating room: a multispecialty international collaboration. New York: Springer; 2015. p. 125\u201349."},{"issue":"3","key":"318_CR9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/archpedi.161.3.282","volume":"161","author":"SS Shah","year":"2007","unstructured":"Shah SS, Hall M, Goodman DM, Feuer P, Sharma V, Fargason C Jr, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161(3):282\u201390.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"318_CR10","unstructured":"Zithromax (azithromycin) [package insert]. Pfizer, Inc. New York, NY; March 30, 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/050670s032,050710s046,050711s043,050784s030lbl.pdf. Accessed 8 Jun 2017."},{"issue":"RR-14","key":"318_CR11","first-page":"1","volume":"54","author":"T Tiwari","year":"2005","unstructured":"Tiwari T, Murphy TV, Moran J. Recommended antimicrobial agents for the treatment and post-exposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep. 2005;54(RR-14):1\u201316.","journal-title":"MMWR Recomm Rep"},{"key":"318_CR12","unstructured":"Fentanyl citrate [package insert]. Hospira Inc. Pfizer Inc. Lake Forest, IL; December 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019115s030s031lbl.pdf. Accessed 8 Jun 2017."},{"key":"318_CR13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-4939-1390-9_9","volume-title":"Pediatric sedation outside of the operating room: a multispecialty international collaboration","author":"RP Prescilla","year":"2015","unstructured":"Prescilla RP. The pharmacology and clinical application of sedatives, analgesics, and adjuncts. In: Manson KP, editor. Pediatric sedation outside of the operating room: a multispecialty international collaboration. New York: Springer; 2015. p. 125\u201349."},{"issue":"2","key":"318_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/pch\/21.2.83","volume":"21","author":"J Corny","year":"2016","unstructured":"Corny J, Bailey B, Lebel D, Bussi\u00e8res JF. Unlicensed and off-label drug use in paediatrics in a mother\u2013child tertiary care hospital. Paediatr Child Health. 2016;21(2):83\u20137.","journal-title":"Paediatr Child Health."},{"key":"318_CR15","unstructured":"Institute for Safe Medication Practices. QuarterWatch (special report, 2014): Adverse drug events in children less than 18\u00a0years old. 2017. https:\/\/www.ismp.org\/newsletters\/acutecare\/showarticle.aspx?id=67. Accessed 01 Aug 2017."},{"issue":"2","key":"318_CR16","doi-asserted-by":"publisher","first-page":"e001868","DOI":"10.1136\/bmjopen-2012-001868","volume":"3","author":"DCB Silva","year":"2013","unstructured":"Silva DCB, Araujo OR, Arduini RG, Alonso CFR, Shibata ARO, Troster EJ. Adverse drug events in a paediatric intensive care unit: a prospective cohort. BMJ Open. 2013;3(2):e001868. https:\/\/doi.org\/10.1136\/bmjopen-2012-001868.","journal-title":"BMJ Open"},{"issue":"5","key":"318_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/PCC.0b013e3181d8e405","volume":"11","author":"S Agarwal","year":"2010","unstructured":"Agarwal S, Classen D, Larsen G, Tofil NM, Hayes LW, Sullivan JE, et al. Prevalence of adverse events in pediatric intensive care units in the United States. Pediatr Crit Care Med. 2010;11(5):568\u201378. https:\/\/doi.org\/10.1097\/PCC.0b013e3181d8e405.","journal-title":"Pediatr Crit Care Med"},{"key":"318_CR18","unstructured":"U.S. Food and Drug Administration. CFR\u2014Code of Federal Regulations Title 21. 2017. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfCFR\/CFRSearch.cfm?fr=201.57. Accessed 30 Dec 2017."},{"key":"318_CR19","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"LL Brunton","year":"2018","unstructured":"Brunton LL, Knollmann BC, Hilal-Dandan R. Goodman and Gilman\u2019s the pharmacological basis of therapeutics. 13th ed. New York: McGraw Hill Medical; 2018.","edition":"13"},{"issue":"3","key":"318_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jsps.2012.09.004","volume":"21","author":"LM Khan","year":"2013","unstructured":"Khan LM, Al-Harthi SE, Saadah OI. Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian university hospital and impact of pharmacovigilance in reporting ADR. Saudi Pharm J. 2013;21(3):261\u20136.","journal-title":"Saudi Pharm J."},{"issue":"4","key":"318_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4103\/0976-500X.85957","volume":"2","author":"R Priyadharsini","year":"2011","unstructured":"Priyadharsini R, Surendiran A, Adithan C, Sreenivasan S, Sahoo FK. A study of adverse drug reactions in pediatric patients. J Pharmacol Pharmacother. 2011;2(4):277\u201380.","journal-title":"J Pharmacol Pharmacother."},{"issue":"1","key":"318_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40360-017-0186-x","volume":"18","author":"AO V\u00e1zquez-Alvarez","year":"2017","unstructured":"V\u00e1zquez-Alvarez AO, Brennan-Bourdon LM, Rinc\u00f3n-S\u00e1nchez AR, Islas-Carbajal MC, Huerta-Olvera SG. Improved drug safety through intensive pharmacovigilance in hospitalized pediatric patients. BMC Pharmacol Toxicol. 2017;18(1):79.","journal-title":"BMC Pharmacol Toxicol."},{"issue":"3","key":"318_CR23","first-page":"186","volume":"20","author":"AS Czaja","year":"2015","unstructured":"Czaja AS, Reiter PD, Schultz ML, Valuck RJ. Patterns of off-label prescribing in the pediatric intensive care unit and prioritizing future research. J Pediatr Pharmacol Ther. 2015;20(3):186\u201396.","journal-title":"J Pediatr Pharmacol Ther."},{"key":"318_CR24","unstructured":"Institute for Safe Medication Practices List of High-Alert Medication. 2017. http:\/\/www.ismp.org\/Tools\/institutionalhighAlert.asp. Accessed 6 Jun 2017."},{"key":"318_CR25","unstructured":"BPCA priority list of pediatric therapeutic needs. 2017. http:\/\/bpca.nichd.nih.gov\/prioritization\/status.cfm. Accessed 6 Jun 2017."},{"key":"318_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00130478-200204000-00007","volume":"3","author":"DH Rhoney","year":"2002","unstructured":"Rhoney DH, Murry KR. National survey on the use of sedatives and neuromuscular blocking agents in the pediatric intensive care unit. Pediatr Crit Care Med. 2002;3:129\u201333.","journal-title":"Pediatr Crit Care Med"},{"issue":"6","key":"318_CR27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1046\/j.1365-2125.2002.t01-3-01689.x","volume":"54","author":"B Horen","year":"2002","unstructured":"Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in pediatric outpatients. Br J Clin Pharmacol. 2002;54(6):665\u201370.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"318_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/106002809603000202","volume":"30","author":"AM Gill","year":"1996","unstructured":"Gill AM, Cousins A, Nunn AJ, Choonara IA. Opiate-induced respiratory depression in pediatric patients. Ann Pharmacother. 1996;30(2):125\u20139.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"318_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/11597920-000000000-00000","volume":"35","author":"AN Rashed","year":"2012","unstructured":"Rashed AN, Wong IC, Cranswick N, Hefele B, Tomlin S, Jackman J, et al. Adverse drug reactions in children\u2013international surveillance and evaluation (ADVISE): a multicentre cohort study. Drug Saf. 2012;35(6):481\u201394.","journal-title":"Drug Saf"},{"issue":"8","key":"318_CR30","first-page":"799","volume":"64","author":"S Kabara","year":"2015","unstructured":"Kabara S, Kagawa T, Ikejima N, Takatsuji S, Sueda A. Side effects of continuous fentanyl infusion for postoperative pain relief in children. Masui. 2015;64(8):799\u2013803.","journal-title":"Masui"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-018-0318-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-018-0318-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-018-0318-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:06:30Z","timestamp":1744715190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-018-0318-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2,5]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1007\/s40272-018-0318-9","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,28]]},"assertion":[{"value":"28 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kazeem A. Oshikoya, Gerold T. Wharton, Debbie Avant, Norman E. Fenn, Allison Lardieri, Edwin Doe, Beena G. Sood, Carol Taketomo, Phuong Lieu, Lilly Yen,\u00a0and Ann W. McMahon have no conflicts of interest. Sara L. Van Driest has been an invited speaker to Merck and received an honorarium. No additional funding was provided for this study. The opinions expressed in this article are those of the authors and should not be interpreted as the position of the US Food and Drug Administration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}]}}